WO2010003232A1 - Traitement du cancer à l’aide d’atractyloside - Google Patents

Traitement du cancer à l’aide d’atractyloside Download PDF

Info

Publication number
WO2010003232A1
WO2010003232A1 PCT/CA2009/000937 CA2009000937W WO2010003232A1 WO 2010003232 A1 WO2010003232 A1 WO 2010003232A1 CA 2009000937 W CA2009000937 W CA 2009000937W WO 2010003232 A1 WO2010003232 A1 WO 2010003232A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
atr
effective amount
therapeutically effective
pharmaceutically acceptable
Prior art date
Application number
PCT/CA2009/000937
Other languages
English (en)
Inventor
Vladimir Pak
Original Assignee
Constab Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constab Pharmaceutical Inc. filed Critical Constab Pharmaceutical Inc.
Publication of WO2010003232A1 publication Critical patent/WO2010003232A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition d’atractyloside (ATR) ou de carboxyatractyloside (CATR) destinée au traitement du cancer. Il est montré que le traitement de tumeurs à l’aide d’ATR réprime la croissance tumorale et amplifie les temps médians de survie dans un modèle de cancer du sein. Il est également montré que des compositions d’ATR sont utiles dans le traitement de tumeurs réfractaires à d’autres protocoles chimiothérapeutiques.
PCT/CA2009/000937 2008-07-07 2009-07-06 Traitement du cancer à l’aide d’atractyloside WO2010003232A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12959108P 2008-07-07 2008-07-07
US61/129,591 2008-07-07

Publications (1)

Publication Number Publication Date
WO2010003232A1 true WO2010003232A1 (fr) 2010-01-14

Family

ID=41506624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/000937 WO2010003232A1 (fr) 2008-07-07 2009-07-06 Traitement du cancer à l’aide d’atractyloside

Country Status (1)

Country Link
WO (1) WO2010003232A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112022864A (zh) * 2020-09-16 2020-12-04 深圳市龙华区中心医院 苍术苷在制备治疗脂肪肝的药物中应用
CN113274420A (zh) * 2021-04-27 2021-08-20 苏州科技大学 一种靶向筛选茅苍术抗乳腺癌活性成分的方法
CN114469967A (zh) * 2021-12-20 2022-05-13 江西中医药大学 一种苍术苷a及其衍生物在制备抗焦虑和抗抑郁药物上的应用
CN115607676A (zh) * 2022-10-19 2023-01-17 中山大学附属第八医院（深圳福田） 羧基苍术苷在制备抗肿瘤耐药性的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2587415Y (zh) * 2002-07-04 2003-11-26 马旭 抗肿瘤药丸
WO2007056852A1 (fr) * 2005-11-15 2007-05-24 Constab Pharmaceutical, Inc. Compositions d'alphafoetoproteine et d'inducteurs d'apoptose pour le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2587415Y (zh) * 2002-07-04 2003-11-26 马旭 抗肿瘤药丸
WO2007056852A1 (fr) * 2005-11-15 2007-05-24 Constab Pharmaceutical, Inc. Compositions d'alphafoetoproteine et d'inducteurs d'apoptose pour le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARTWELL, J.L.: "Bioactive Plants", vol. 2, 1982, QUARTERMAN PUBLICATIONS, ISBN: 0880001305, article "Plants used against cancer: a survey" *
PAK V.: "The Use of AFP-Complexes to Induce Apoptosis in Cancer Cells.", THE OPEN CANCER JOURNAL, vol. 2, 20 May 2008 (2008-05-20), pages 12 - 14, ISSN: 1874-0790, Retrieved from the Internet <URL:http://bentham.org/open/tocj/openaccess2.htmD4> *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112022864A (zh) * 2020-09-16 2020-12-04 深圳市龙华区中心医院 苍术苷在制备治疗脂肪肝的药物中应用
CN113274420A (zh) * 2021-04-27 2021-08-20 苏州科技大学 一种靶向筛选茅苍术抗乳腺癌活性成分的方法
CN114469967A (zh) * 2021-12-20 2022-05-13 江西中医药大学 一种苍术苷a及其衍生物在制备抗焦虑和抗抑郁药物上的应用
CN114469967B (zh) * 2021-12-20 2024-02-20 江西中医药大学 一种苍术苷a及其衍生物在制备抗焦虑和抗抑郁药物上的应用
CN115607676A (zh) * 2022-10-19 2023-01-17 中山大学附属第八医院（深圳福田） 羧基苍术苷在制备抗肿瘤耐药性的药物中的应用
CN115607676B (zh) * 2022-10-19 2024-03-01 中山大学附属第八医院（深圳福田） 羧基苍术苷在制备抗肿瘤耐药性的药物中的应用

Similar Documents

Publication Publication Date Title
US7326734B2 (en) Treatment of bladder and urinary tract cancers
AbuKhader Thymoquinone in the clinical treatment of cancer: Fact or fiction?
ES2280527T3 (es) Una composicion farmaceutica de jasmonato para tratamiento del cancer.
US20130079401A1 (en) Novel use of isothiocyanates for treating cancer
AU2010243267A1 (en) Pentamidine combinations for treating cancer
EP1067941A1 (fr) Composition antitumorale contenant une composition synergetique d&#39;un derive d&#39;anthracycline et d&#39;un derive de campothecine
JP2019123728A (ja) 化学療法耐性を克服するためのウィルホルリドａの使用
WO2019227167A1 (fr) Compositions et traitements
WO2010003232A1 (fr) Traitement du cancer à l’aide d’atractyloside
Peredo-Silva et al. Derivatives of alkyl gallate triphenylphosphonium exhibit antitumor activity in a syngeneic murine model of mammary adenocarcinoma
EP2175849A1 (fr) Traitement de mélanome
EP3003367B1 (fr) Compositions pour réduire ou prévenir les métastases
WO2009109109A1 (fr) Utilisation de polyphénols de thé dans la préparation de médicaments destinés à la prévention ou au traitement de tumeurs
EP3151864B1 (fr) Traitement combiné comprenant un promédicament liposomal de la mitomycine c et une radiothérapie
JP2017535617A (ja) 中皮腫の処置において使用するためのシナラ・スコリムスの滴定抽出物
US20090186835A1 (en) Treatment and prophylaxis of cancer
EP1849467A1 (fr) Preparation pharmaceutique synergique contenant de la baicaleine et de la baicaline et destinee a l&#39;inhibition d&#39;une tumeur
JP6367801B2 (ja) 化学療法耐性を克服するための、トリプテリジウム・ウィルフォルディ由来の抽出物の使用
EP3043809B1 (fr) Extrait de filipendula vulgaris et utilisations de celui-ci
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
CN1520823A (zh) 一种新型的抗肿瘤药物复方制备方法
Dash et al. Antitumor activity and antioxidant role of Ichnocarpus frutescens against Ehrlich ascites carcinoma in swiss albino mice
TW201444561A (zh) 可治療癌症之藥學組合物
Sanjukta et al. ROLE OF ISOFLAVONES IN DRUG DELIVERY WITH SPECIAL REFERENCE TO CHICKEN EGG LYSOZYME ON ASCITE CARCINOMA CELL: EXPERIENCED BASED RESEARCH
CA2242406C (fr) Poison topo-isomerase ii et therapie associee a base de derives de bis-dioxypiperazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793748

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09793748

Country of ref document: EP

Kind code of ref document: A1